Literature DB >> 30393607

Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy.

Umberto Malapelle1, Antonino Iaccarino1, Antonio Rossi2.   

Abstract

Entities:  

Year:  2018        PMID： 30393607      PMCID： PMC6193894          DOI： 10.21037/tlcr.2018.08.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  11 in total

1.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.

Authors:  Eleanor Russell-Goldman; Sasha Kravets; Suzanne E Dahlberg; Lynette M Sholl; Marina Vivero
Journal:  Cancer Cytopathol       Date:  2018-02-05       Impact factor: 5.284

3.  Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  S Novello; F Barlesi; R Califano; T Cufer; S Ekman; M Giaj Levra; K Kerr; S Popat; M Reck; S Senan; G V Simo; J Vansteenkiste; S Peters
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

4.  PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Authors:  Ming Sound Tsao; Keith M Kerr; Mark Kockx; Mary-Beth Beasley; Alain C Borczuk; Johan Botling; Lukas Bubendorf; Lucian Chirieac; Gang Chen; Teh-Ying Chou; Jin-Haeng Chung; Sanja Dacic; Sylvie Lantuejoul; Mari Mino-Kenudson; Andre L Moreira; Andrew G Nicholson; Masayuki Noguchi; Giuseppe Pelosi; Claudia Poleri; Prudence A Russell; Jennifer Sauter; Erik Thunnissen; Ignacio Wistuba; Hui Yu; Murry W Wynes; Melania Pintilie; Yasushi Yatabe; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2018-05-22       Impact factor: 15.609

5.  Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.

Authors:  Birgit G Skov; Torsten Skov
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-08

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.

Authors:  Sean P Stoy; Lauren Rosen; Jeffrey Mueller; Septimiu Murgu
Journal:  Cancer Cytopathol       Date:  2017-10-20       Impact factor: 5.284

8.  EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.

Authors:  Umberto Malapelle; Claudio Bellevicine; Caterina De Luca; Maria Salatiello; Alfonso De Stefano; Danilo Rocco; Nicla de Rosa; Fabiana Vitiello; Stefania Russo; Francesco Pepe; Antonino Iaccarino; Pietro Micheli; Alfonso Illiano; Chiara Carlomagno; Franco Vito Piantedosi; Giancarlo Troncone
Journal:  Cancer Cytopathol       Date:  2013-06-18       Impact factor: 5.284

9.  Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.

Authors:  Umberto Malapelle; Clara Mayo de-Las-Casas; Danilo Rocco; Monica Garzon; Pasquale Pisapia; Nuria Jordana-Ariza; Maria Russo; Roberta Sgariglia; Caterina De Luca; Francesco Pepe; Alejandro Martinez-Bueno; Daniela Morales-Espinosa; María González-Cao; Niki Karachaliou; Santiago Viteri Ramirez; Claudio Bellevicine; Miguel Angel Molina-Vila; Rafael Rosell; Giancarlo Troncone
Journal:  Br J Cancer       Date:  2017-02-07       Impact factor: 7.640

10.  PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

Authors:  Vanda F Torous; Deepa Rangachari; Benjamin P Gallant; Meghan Shea; Daniel B Costa; Paul A VanderLaan
Journal:  J Am Soc Cytopathol       Date:  2018-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.